Verastem is a biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells. The company’s products candidates include VS-507, currently in preclinical studies for the treatment for breast cancer; and VS-4718 and VS-5095, which are in preclinical trials for cancers. The company’s product candidates target CSCs that have been implicated in aggressive cancers, metastasis, and chemotherapeutic resistance. For more information visit the company’s Web site at www.verastem.com.

Rodman & Renshaw is a full-service investment bank dedicated to providing corporate finance, strategic advisory, and related services to public and private companies across multiple sectors and regions. Rodman also provides research, sales, and trading services. According to Sagient Research Systems, Rodman has been ranked the #1 Placement Agent in terms of the aggregate number of PIPE and RD financing transactions completed every year since 2005. For more information on Rodman & Renshaw, visit www.rodmanandrenshaw.com.

Let us hear your thoughts below: